JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Canada, US Hold Fresh Trade Talks as August 19 Tariff Deadline Nears 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Singapore Raises 2026 GDP Growth Forecast as AI Demand Fuels Economy 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Dollar Steady as Markets Await U.S. Inflation Data 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Add as a preferred source on Google
Roche Diagnostics Korea revealed on Thursday, May 6, that it was granted approval for its Cobas test, a testing device used to detect severe acute respiratory syndrome coronavirus in laboratories.
Roche Diagnostic’s Cobas test - What it is
The Korea Herald reported that Roche Diagnostics Korea said that its Cobas test is not only effective in qualitative detection, but it can also differentiate between SARS-CoV-2, Influenza A, and Influenza B that may be present in nasal swab samples from individuals undergoing test for possible respiratory infection.
It was added that Roche’s Cobas SARS-CoV-2 test could also be utilized in the company’s automated molecular testing solutions, called the cobas 6800/8800 Systems. This has the capacity to furnish up to 96 results in as little as three hours, while the cobas 8800 System can give 960 results within eight hours.
Moreover, Roche’s cobas SARS-CoV-2 test boasts of more than 97% test sensitivity, thus allowing a more accurate identification if a virus is present or not. The company added that this can deliver results fast and accurately so that doctors can give the right diagnosis and prescribe the right treatment for the case.
Roche increased investment in S. Korea
Meanwhile, Roche Diagnostics AG is headquartered in Basel, Switzerland, and because it saw how South Korea responded to the COVID-19 pandemic, the company said it is investing more in Roche Korea due to its excellent response to the crisis.
“Compared to other countries, Korea has been controlling Covid-19 well,” Korea BioMed Review quoted Roche Diagnostics Korea’s general manager, Johnny Tse, as saying. “But it needs to prepare for the next stage. Most Covid-19 tests use PCR (polymerase chain reaction) but we may need antibody/antigen tests, rapid testing for crossing borders, or tests based on the progress of the disease (Covid-19).”
Roche made the right decision to invest more since the cobas SARS-CoV-2 test has finally been approved after efforts were exerted to produce this device that will help detect COVID-19 more accurately. Finally, Tse said that they are planning to continue investing in S. Korea and create more of the things that are needed in helping curb highly infectious diseases.
